Anti-GPRC5D CAR T cells might be a very potential candidate treatment for patients with MM progressed after anti-BCMA CAR T-cell therapy or refractory to anti-BCMA CAR T cells. The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.